Você procurou por: protocol defined non inferiority (Inglês - Maltês)

protocol defined major bleeding
fsad maġġuri definit skont il- protokol

non-inferiority margin
marġini ta’ non-inferjorità

non-inferiority p-value (hr)
il-valur p (hr) mhux ta’ inferjorità

all seven common serotypes met pre-defined non-inferiority criteria for igg elisa gmcs.
is-seba’ serotipi komuni kollha, issodisfaw il-kriterji pre-definiti tan-nuqqas ta’ inferjorità għal igg elisa gmcs.

^ blinded independent review (protocol-defined primary analysis)
^ analiżi indipendenti u blinded (analiżi primarja definita mill-protokoll)

immunologic non-inferiority to 7-valent prevenar
non-inferjorità immunoloġika għal prevenar 7-valenti

ap<0.0001 for assessment of non-inferiority to prn
ap<0.0001 għall-valutazzjoni ta’ nuqqas ta’ inferjorità għal prn

rosiglitazone failed to demonstrate non-inferiority to metformin.
rosiglitazone ma weriex li m’huwiex inferjuri għall-metformin.

conclusions supported non-inferiority regardless of analysis method.
il-konklużjonijiet appoġġjaw in-nuqqas ta’ inferjorità irrispettivament mill-metodu ta’ analiżi.

the non-inferiority analysis of study no16967 primary analysis
riżultati importanti ta ’ no16967

95% ci for hr non-inferiority p-value (hr)
95% ci għal hr il- valur- p (hr) mhux inferjuri

this study failed to demonstrate non-inferiority of rotigotine to ropinirole.
dan l-istudju ma rnexxilux juri li rotigotine mhux inferjuri għal ropinirole.

the prespecified non-inferiority margin for the treatment difference was 20%.
il-marġni ta’ nuqqas ta’ inferjorità speċifikat minn qabel għad-differenza fil-kura kien ta’ 20%.

table 10 key efficacy results for the non-inferiority analysis of study no16967
tabella 10 riżultati importanti ta’ l-effikaċja għall-analiżi ta’ nuqqas ta’ inferjorità ta’ studju no16967

the resistance outcome for patients with protocol defined virological failure and phenotypic resistance at week 96 are shown in table 6:
ir- riżultat tar-reżistenza għal pazjenti b’insuffiċjenza viroloġika u reżistenza fenotipika f’ġimgħa 96 qed jintwerew f’tabella 6:

similar efficacy for rilpivirine was seen in each trial demonstrating non-inferiority to efavirenz.
effikaċja tixxiebah għal rilpivirine dehret f’kull prova, bir-riżultat li ntwera nuqqas ta’ inferjorità għal efavirenz.

however, both analyses were compatible with a conclusion of non-inferiority between both treatment arms.
fl- analiżi kif trattat (as treated jew at), id- differenza bejn iż- żewġ friegħi kienet aktar ċara (88% fil - grupp ta ’ abacavir mqabbla ma ’ 95% tal- pazjenti fil- grupp ta ’ zidovudine (point estimate ta ’ differenza fil- kura: - 6. 8, 95% ci – 11. 8; - 1. 7), iż- żewġ analiżi iżda, kienu jaqblu mal- konklużżjoni li ma kien hemm ebda inferjorita ’ bejn i ż- żewġ friegħi ta ’ kura.

comparison of mean diurnal iop (mmhg) change from baseline– non-inferiority study
paragun tal-bidla medja fl-iop (mmhg) ta’ matul il-Ġurnata mil-linja bażi – studju dwar nuqqas ta’ inferjorità

efficacy was based on demonstrating non-inferiority of oral palonosetron doses compared to the approved intravenous formulation.
l-effikaċja kienet ibbażata fuq l-osservazzjoni ta’ non-inferjorità ta’ dożi orali ta’ palonosetron meta mqabbel mal-formulazzjoni approvata biex tingħata ġol-vini.

0.89 (0.70, 1.13) p-value < 0.0001 (non-inferiority)
0.89 (0.70, 1.13) valur p < 0.0001 (non-inferjorità)